Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2022-05-05 00:00:00 ET · period of report 2022-01-06 · accession 0000899243-22-016853 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-05 | 2022-01-11 | AMLX | ALS Invest 1 B.V. | 10% | C - Cnv Deriv | — | +5.96M | 1.13M | New | — |
| DM | 2022-05-05 | 2022-01-11 | AMLX | ALS Invest 1 B.V. | 10% | C - Cnv Deriv | $0.00 | -5.96M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-11 | C | A | 4,826,503 | — | 5,955,889 | D | — | — | (F1) Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. (F2) The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. |
| 2 | Common | Common Stock | 2022-01-11 | C | A | 1,129,386 | — | 1,129,386 | D | — | — | (F1) Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. (F2) The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. |
| 3 | Derivative | Series B Preferred Stock | 2022-01-11 | C | D | 4,826,503 | $0.00 | 0 | D | — · — to — | 4,826,503 Common Stock | (F2) The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. (F1) Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. |
| 4 | Derivative | Series A Preferred Stock | 2022-01-11 | C | D | 1,129,386 | $0.00 | 0 | D | — · — to — | 1,129,386 Common Stock | (F2) The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person. (F1) Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. |